Companies Voyager Therapeutics, Inc.
Voyager Therapeutics (VYGR): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Voyager Therapeutics, Inc.’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers24th pct.Of 17 peer CEOs
CEO pay, last three years
- $3,172,433FY2023
- $3,377,401FY2024
- $2,508,370FY2025
CEO total pay was $2,508,370 in fiscal 2025, down from $3,377,401 in fiscal 2024.
FY2025: salary $674,903 · bonus $0 · stock awards $611,900 · option awards $843,900
Executives and directors
Alfred Sandrock · CEOJacquelyn Fahey Sandell · General CounselRobin Swartz · COOToby Ferguson · Chief Medical OfficerCatherine J. Mackey · Independent DirectorGeorge Scangos · Independent DirectorGlenn Pierce · Independent DirectorGrace E. Colón · Independent DirectorJames A. Geraghty · Independent DirectorJude Onyia · DirectorMichael Higgins · Chair of the BoardNancy Vitale · Independent DirectorSteven Hyman · Independent Director
Frequently asked questions
Who was the highest-paid executive at Voyager Therapeutics, Inc. in fiscal 2025?
As disclosed, Alfred Sandrock (Chief Executive Officer, President, and Director) was the highest-paid executive at Voyager Therapeutics, Inc. in fiscal 2025, with total compensation of $2,508,370.
How does Voyager Therapeutics, Inc.'s chief executive pay compare to its disclosed peer group?
As disclosed, Alfred Sandrock's total compensation ranked at the 24th percentile of Voyager Therapeutics, Inc.'s disclosed peer group.
How did shareholders vote on Voyager Therapeutics, Inc.'s executive compensation?
As disclosed, 97.24% of shareholders supported Voyager Therapeutics, Inc.'s executive compensation in the latest say-on-pay vote.
How much does Voyager Therapeutics, Inc. spend in total on board compensation for fiscal 2025?
As disclosed, Voyager Therapeutics, Inc. reported total board compensation of $508,000 for fiscal 2025.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Alfred Sandrock | $674,903 | $0 | $611,900 | $843,900 | $361,917 | $0 | $15,750 | $2,508,370 |
| Chief Executive Officer, President, and Director | ||||||||
| Jacquelyn Fahey Sandell | 297,842 | 0 | 175,130 | 241,530 | 0 | 0 | 760,484 | 1,474,986 |
| Former Chief Legal Officer | ||||||||
| Robin Swartz | 520,190 | 0 | 300,675 | 414,675 | 205,475 | 0 | 13,285 | 1,454,300 |
| Chief Business Officer & Chief Operating Officer | ||||||||
| Toby Ferguson | 513,369 | 0 | 265,860 | 366,660 | 202,781 | 0 | 15,750 | 1,364,420 |
| Former Chief Medical Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Alfred Sandrock | $2,508,370 | $3,377,401 | $3,172,433 | ↓ −869,031 |
| Jacquelyn Fahey Sandell | 1,474,986 | — | 1,677,297 | — |
| Robin Swartz | 1,454,300 | — | 1,381,272 | — |
| Toby Ferguson | 1,364,420 | 2,969,200 | — | ↓ −1,604,780 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
Voyager's compensation programs are designed to: attract and retain individuals with superior ability, technical, and managerial experience; align executive officers' incentives with our corporate strategies, business objectives and the long-term interests of our stockholders; and increase the incentive to achieve key strategic performance measures by linking incentive award opportunities to the achievement of performance objectives, and by providing a portion of total compensation for executive officers in the form of ownership in the Company.
| CEO STI target (% of salary) | 55% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Alpine Rewards, LLC |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Jacquelyn Fahey Sandell | OPTION | — | — | — | — | — | $241,530 |
| Robin Swartz | OPTION | — | — | — | — | — | 414,675 |
| Alfred Sandrock | PRSU | — | — | — | — | — | 611,900 |
| Toby Ferguson | PRSU | — | — | — | — | — | 265,860 |
| Alfred Sandrock | OPTION | — | — | — | — | — | 843,900 |
| Jacquelyn Fahey Sandell | PRSU | — | — | — | — | — | 175,130 |
| Robin Swartz | PRSU | — | — | — | — | — | 300,675 |
| Toby Ferguson | OPTION | — | — | — | — | — | 366,660 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Jacquelyn Fahey Sandell | $0 | $0 | $241,530 | 0.0% |
| Robin Swartz | 0 | 0 | 414,675 | 0.0% |
| Alfred Sandrock | 0 | 0 | 843,900 | 0.0% |
| Toby Ferguson | 0 | 0 | 366,660 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Robin Swartz | Option | 2,500 | 2.85 | — |
| Alfred Sandrock | Option | 2,750 | 3.32 | — |
| Robin Swartz | Option | 5,200 | 3.32 | — |
| Robin Swartz | RSU | 13,333 | — | 52,399 |
| Robin Swartz | Option | 23,334 | 7.43 | — |
| Alfred Sandrock | RSU | 25,000 | — | 98,250 |
| Robin Swartz | RSU | 33,334 | — | 131,003 |
| Alfred Sandrock | RSU | 40,000 | — | 157,200 |
| Robin Swartz | Option | 56,000 | 7.6 | — |
| Alfred Sandrock | Option | 58,788 | 8.55 | — |
| Toby Ferguson | RSU | 63,000 | — | 247,590 |
| Toby Ferguson | RSU | 70,000 | — | 275,100 |
| Alfred Sandrock | Option | 70,000 | 7.43 | — |
| Robin Swartz | RSU | 71,250 | — | 280,013 |
| Robin Swartz | RSU | 78,000 | — | 306,540 |
| Toby Ferguson | RSU | 78,000 | — | 306,540 |
| Alfred Sandrock | RSU | 86,667 | — | 340,601 |
| Toby Ferguson | Option | 100,800 | 4.22 | — |
| Robin Swartz | Option | 114,000 | 4.22 | — |
| Toby Ferguson | Option | 118,125 | 9.26 | — |
| Alfred Sandrock | RSU | 145,000 | — | 569,850 |
| Alfred Sandrock | Option | 145,600 | 7.6 | — |
| Alfred Sandrock | RSU | 231,000 | — | 907,830 |
| Alfred Sandrock | Option | 232,000 | 4.22 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Michael HigginsIndependent · Board Chair · Audit (Chair) · Compensation · Nominating/Governance | $92,500 | $0 | $53,760 | $0 | $0 | $146,260 |
| Nancy VitaleIndependent · Compensation (Chair) · Nominating/Governance | 55,000 | 0 | 53,760 | 0 | 0 | 108,760 |
| Grace E. ColónIndependent · Audit · Compensation | 54,000 | 0 | 53,760 | 0 | 0 | 107,760 |
| Steven HymanIndependent · Audit · Science and Technology (Chair) | 54,000 | 0 | 53,760 | 0 | 0 | 107,760 |
| James A. GeraghtyIndependent · Audit · Nominating/Governance | 53,500 | 0 | 53,760 | 0 | 0 | 107,260 |
| Catherine J. MackeyIndependent · Audit · Science and Technology | 53,000 | 0 | 53,760 | 0 | 0 | 106,760 |
| Glenn PierceIndependent · Compensation · Science and Technology | 51,000 | 0 | 53,760 | 0 | 0 | 104,760 |
| George ScangosIndependent · Science and Technology · Nominating/Governance (Chair) | 50,000 | 0 | 53,760 | 0 | 0 | 103,760 |
| Jude OnyiaNot independent · Science and Technology | 45,000 | 0 | 53,760 | 0 | 0 | 98,760 |
| Alfred SandrockEmployee director | 0 | 0 | 0 | — | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 16,000 / 12,500 / 10,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $508,000 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $508,000 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Voyager Therapeutics as a peer
Companies that benchmark against VYGR
7 companies name VYGR as a compensation peer
- Adaptive Biotechnologies CorpADPTFY2025
- Adverum Biotechnologies, Inc.ADVMFY2024
- AGENUS INCAGENFY2025
- Editas Medicine, Inc.EDITFY2025
- Generation Bio Co.GBIOFY2024
- Seres Therapeutics, Inc.MCRBFY2025
- uniQure N.V.QUREFY2025
Each company listed discloses VYGR in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named VYGR in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
ADVM Adverum Biotechnologies, Inc.GLUE Monte Rosa Therapeutics, Inc.STOK Stoke Therapeutics, Inc.EDIT Editas Medicine, Inc.TNYA Tenaya Therapeutics, Inc.TRDA Entrada Therapeutics, Inc.PEPG PepGen, Inc.VERV Verve Therapeutics, Inc.PRLD Prelude Therapeutics Inc.PRME Prime Medicine, Inc.WVE Wave Life Sciences Ltd.VIGL Vigil Neuroscience, Inc.FHTX Foghorn Therapeutics, Inc.LXEO Lexeo Therapeutics, Inc.MGTX MeiraGTx Holdings plcSLDB Solid Biosciences, Inc.NGNE Neurogene, Inc.
Peer reciprocity
The companies Voyager Therapeutics, Inc. names as compensation peers that name it back in their own disclosed peer groups.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Stoke Therapeutics, Inc. | 2025 | Ian Smith | $170,625 | $11,590,000 | $14,035,067 | $0 | $27,031,655 |
| 2 | Wave Life Sciences Ltd. | 2025 | Paul Bolno | 700,000 | 1,420,540 | 9,506,300 | 614,250 | 12,277,916 |
| 3 | MeiraGTx Holdings plc | 2025 | Alexandria Forbes | 840,000 | 5,823,500 | — | — | 8,330,006 |
| 4 | Verve Therapeutics, Inc. | 2024 | Sekar Kathiresan | 639,231 | 1,683,000 | 4,727,372 | 378,972 | 7,442,663 |
| 5 | Solid Biosciences, Inc. | 2025 | Alexander Cumbo | 650,988 | 2,318,275 | 1,792,397 | 0 | 5,223,442 |
| 6 | Monte Rosa Therapeutics, Inc. | 2025 | Markus Warmuth | 650,000 | 910,080 | 3,043,648 | 429,000 | 5,032,728 |
| 7 | Adverum Biotechnologies, Inc. | 2024 | Laurent Fischer | 691,795 | 171,363 | 2,839,252 | 415,080 | 4,131,290 |
| 8 | Prime Medicine, Inc. | 2025 | Allan Reine | 606,212 | 0 | 2,828,798 | 402,000 | 3,894,187 |
| 9 | Entrada Therapeutics, Inc. | 2025 | Dipal Doshi | 635,000 | 1,387,428 | 1,452,059 | 349,250 | 3,837,737 |
| 10 | Lexeo Therapeutics, Inc. | 2025 | R. Nolan Townsend | 632,700 | 1,493,488 | 1,165,982 | 347,985 | 3,650,940 |
| 11 | PepGen, Inc. | 2025 | James McArthur | 619,000 | 170,620 | 2,088,547 | 0 | 3,316,783 |
| 12 | Neurogene, Inc. | 2025 | Rachel McMinn | 618,800 | 385,746 | 1,826,570 | 0 | 3,209,553 |
| 13 | Vigil Neuroscience, Inc. | 2024 | Ivana Magovčević-Liebisch | 620,000 | 0 | 1,692,871 | 306,900 | 2,633,571 |
| 14 | Voyager Therapeutics, Inc. | 2025 | Alfred Sandrock | 674,903 | 611,900 | 843,900 | 361,917 | 2,508,370 |
| 15 | Foghorn Therapeutics, Inc. | 2025 | Adrian Gottschalk | 638,000 | 0 | 1,334,037 | 385,990 | 2,361,027 |
| 16 | Editas Medicine, Inc. | 2025 | Gilmore O'Neill | 686,574 | 0 | 1,282,937 | 375,164 | 2,353,655 |
| 17 | Tenaya Therapeutics, Inc. | 2025 | Faraz Ali | 664,173 | 141,924 | 755,507 | 319,275 | 1,881,396 |
| 18 | Prelude Therapeutics Inc. | 2025 | Krishna Vaddi | 615,441 | 0 | 412,744 | 309,465 | 1,348,000 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Voyager Therapeutics, Inc. | 97.5% | not disclosed | No | Alpine Rewards, LLC |
| Adverum Biotechnologies, Inc. | not disclosed | not disclosed | not disclosed | Aon |
| Editas Medicine, Inc. | 91% | Options 100 | not disclosed | Pearl Meyer & Partners, LLC |
| Entrada Therapeutics, Inc. | not disclosed | not disclosed | No | Pay Governance |
| Foghorn Therapeutics, Inc. | not disclosed | Options 100 | not disclosed | Pay Governance, LLC |
| Lexeo Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | Alpine Rewards, LLC |
| MeiraGTx Holdings plc | not disclosed | RSU 100 | not disclosed | Total Compensation Solutions |
| Monte Rosa Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | Radford, an Aon Hewitt Company |
| Neurogene, Inc. | not disclosed | not disclosed | not disclosed | Aon |
| PepGen, Inc. | not disclosed | not disclosed | not disclosed | Pay Governance, LLC |
| Prelude Therapeutics Inc. | not disclosed | Option 100 | not disclosed | Compensia |
| Prime Medicine, Inc. | 120% | not disclosed | not disclosed | Alpine Rewards |
| Solid Biosciences, Inc. | 100% | not disclosed | No | Radford (AON Hewitt) |
| Stoke Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | Aon |
| Tenaya Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | Pearl Meyer |
| Verve Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | Radford Data & Analytics from Aon plc |
| Vigil Neuroscience, Inc. | not disclosed | Option 100 | not disclosed | Aon |
| Wave Life Sciences Ltd. | 135% | not disclosed | not disclosed | Aon Consulting Inc. |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-09 | 32,041,373 | 910,087 | 157,037 | 97.24% | Passed |
| 2025 | 2025-06-03 | 37,755,432 | 2,034,622 | 108,040 | 94.89% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-06-09 | 97.24%a |
| 2025 | 2025-06-03 | 94.89%b |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | — |
|---|---|
| CEO total compensation | — |
| Median employee compensation | — |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| George Scangos | Director | 2026-06-09 | A | 30,000 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| James A. Geraghty | Director | 2026-06-09 | A | 30,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Higgins | Director | 2026-06-09 | A | 30,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Nancy Vitale | Director | 2026-06-09 | A | 30,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven Hyman | Director | 2026-06-09 | A | 30,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Glenn Pierce | Director | 2026-06-09 | A | 30,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jude Onyia | Director | 2026-06-09 | A | 30,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Grace Colon | Director | 2026-06-09 | A | 30,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Catherine J. Mackey | Director | 2026-06-09 | A | 30,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Todd Alfred Carter | Chief Scientific Officer | 2026-11-01 | A | 154,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Todd Alfred Carter | Chief Scientific Officer | 2026-11-01 | A | 33,000 | 0 | 0 | Common | Form 4 ↗ |
| Robin Swartz | President | 2026-11-01 | A | 318,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robin Swartz | President | 2026-11-01 | A | 68,250 | 0 | 0 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (62 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Alfred Sandrock. DEF 14A, filed 2026-04-28. Section “Summary Compensation Table” · page 27. As printed: 2,508,370. View filing ↗
- Section 01, Jacquelyn Fahey Sandell. DEF 14A, filed 2026-04-28. Section “Summary Compensation Table”. As printed: 1,474,986. View filing ↗
- Section 01, Robin Swartz. DEF 14A, filed 2026-04-28. Section “Summary Compensation Table”. As printed: 1,454,300. View filing ↗
- Section 01, Toby Ferguson. DEF 14A, filed 2026-04-28. Section “Summary Compensation Table”. As printed: 1,364,420. View filing ↗
- Section 03, Jacquelyn Fahey Sandell OPTION. DEF 14A, filed 2026-04-28. Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 03, Robin Swartz OPTION. DEF 14A, filed 2026-04-28. Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 03, Alfred Sandrock PRSU. DEF 14A, filed 2026-04-28. Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 03, Toby Ferguson PRSU. DEF 14A, filed 2026-04-28. Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 03, Alfred Sandrock OPTION. DEF 14A, filed 2026-04-28. Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 03, Jacquelyn Fahey Sandell PRSU. DEF 14A, filed 2026-04-28. Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 03, Robin Swartz PRSU. DEF 14A, filed 2026-04-28. Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 03, Toby Ferguson OPTION. DEF 14A, filed 2026-04-28. Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2026-04-28. Section “CEO Pay Ratio”. As printed: —. View filing ↗
- Section 08, Michael Higgins. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 146,260. View filing ↗
- Section 08, Nancy Vitale. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 108,760. View filing ↗
- Section 08, Grace E. Colón. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 107,760. View filing ↗
- Section 08, Steven Hyman. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 107,760. View filing ↗
- Section 08, James A. Geraghty. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 107,260. View filing ↗
- Section 08, Catherine J. Mackey. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 106,760. View filing ↗
- Section 08, Glenn Pierce. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 104,760. View filing ↗
- Section 08, George Scangos. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 103,760. View filing ↗
- Section 08, Jude Onyia. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 98,760. View filing ↗
- Section 08, Alfred Sandrock. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, George Scangos 2026-06-09. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James A. Geraghty 2026-06-09. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Higgins 2026-06-09. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Nancy Vitale 2026-06-09. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven Hyman 2026-06-09. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Glenn Pierce 2026-06-09. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jude Onyia 2026-06-09. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Grace Colon 2026-06-09. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Catherine J. Mackey 2026-06-09. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Todd Alfred Carter 2026-11-01. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Todd Alfred Carter 2026-11-01. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Robin Swartz 2026-11-01. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Robin Swartz 2026-11-01. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-06-10. Item 5.07 · say-on-pay result. As reported: 97.24% (votes for as printed: 32,041,373). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-06-05. Item 5.07 · say-on-pay result. As reported: 94.89% (votes for as printed: 37,755,432). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 508,000 + equity 0 + all other 0 = 508,000, summed across the director compensation table rows.
- Stoke Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Stoke Therapeutics, Inc.'s own proxy. As printed: 27,031,655. View filing ↗
- Wave Life Sciences Ltd., Section 10b CEO total. DEF 14A, filed 2026-10-14. CEO total compensation as printed in Wave Life Sciences Ltd.'s own proxy. As printed: 12,277,916. View filing ↗
- MeiraGTx Holdings plc, Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in MeiraGTx Holdings plc's own proxy. As printed: 8,330,006. View filing ↗
- Verve Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-25. CEO total compensation as printed in Verve Therapeutics, Inc.'s own proxy. As printed: 7,442,663. View filing ↗
- Solid Biosciences, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Solid Biosciences, Inc.'s own proxy. As printed: 5,223,442. View filing ↗
- Monte Rosa Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Monte Rosa Therapeutics, Inc.'s own proxy. As printed: 5,032,728. View filing ↗
- Adverum Biotechnologies, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-28. CEO total compensation as printed in Adverum Biotechnologies, Inc.'s own proxy. As printed: 4,131,290. View filing ↗
- Prime Medicine, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Prime Medicine, Inc.'s own proxy. As printed: 3,894,187. View filing ↗
- Entrada Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Entrada Therapeutics, Inc.'s own proxy. As printed: 3,837,737. View filing ↗
- Lexeo Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Lexeo Therapeutics, Inc.'s own proxy. As printed: 3,650,940. View filing ↗
- PepGen, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in PepGen, Inc.'s own proxy. As printed: 3,316,783. View filing ↗
- Neurogene, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-16. CEO total compensation as printed in Neurogene, Inc.'s own proxy. As printed: 3,209,553. View filing ↗
- Vigil Neuroscience, Inc., Section 10b CEO total. DEF 14A, filed 2025-03-31. CEO total compensation as printed in Vigil Neuroscience, Inc.'s own proxy. As printed: 2,633,571. View filing ↗
- Voyager Therapeutics, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Voyager Therapeutics, Inc.'s own proxy. As printed: 2,508,370. View filing ↗
- Foghorn Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Foghorn Therapeutics, Inc.'s own proxy. As printed: 2,361,027. View filing ↗
- Editas Medicine, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Editas Medicine, Inc.'s own proxy. As printed: 2,353,655. View filing ↗
- Tenaya Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-16. CEO total compensation as printed in Tenaya Therapeutics, Inc.'s own proxy. As printed: 1,881,396. View filing ↗
- Prelude Therapeutics Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Prelude Therapeutics Inc.'s own proxy. As printed: 1,348,000. View filing ↗
- Section 10a, Adverum Biotechnologies, Inc. reciprocity. DEF 14A. Adverum Biotechnologies, Inc. names Voyager Therapeutics, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Editas Medicine, Inc. reciprocity. DEF 14A. Editas Medicine, Inc. names Voyager Therapeutics, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, MeiraGTx Holdings plc reciprocity. DEF 14A. MeiraGTx Holdings plc names Voyager Therapeutics, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗